CJC-1295 + Ipamorelin (5mg/5mg) · Research brief

CJC-1295: Mechanism, Research Literature, and Lab Handling

Real Peptides Research TeamEditorial

Updated September 5, 202610 min read

52 WORDS

Short answer

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), built from the first 29 amino acids of human GHRH with four amino acid substitutions and, in one variant, an albumin-binding linker. Developed in the early 2000s, it is studied in laboratory settings for its effects on growth hormone and IGF-1 signaling.

Key takeaways

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) based on the GRF(1-29) fragment with four stabilizing amino acid substitutions.
Two variants circulate in research settings: the DAC version, which carries an albumin-binding linker and a reported half-life measured in days, and the no-DAC version (modified GRF 1-29), reported to clear within roughly half an hour.
Early clinical work in healthy adults reports sustained elevations in growth hormone and IGF-1, with GH secretion remaining pulsatile rather than becoming continuous.
Much of the newer published literature is analytical — LC-MS/MS and immuno-PCR detection methods developed for equine anti-doping — rather than efficacy work in humans.
CJC-1295 is not an FDA-approved drug for any of the applications discussed here and is supplied for laboratory research only.
Supplier evaluation rests on batch-specific third-party COAs: HPLC purity, mass spectrometry identity confirmation, and traceable lot numbers.

What CJC-1295 Is and Where It Came From

Native human GHRH is a 44-amino-acid hypothalamic peptide. Decades of endocrine work established that its biological activity lives almost entirely in the first 29 residues — the fragment known as GRF(1-29), or sermorelin. That fragment has an obvious practical problem for researchers: it degrades quickly, chiefly through cleavage by dipeptidyl peptidase-4 (DPP-4) at the N-terminus, giving it a plasma half-life measured in minutes.

CJC-1295 was designed by the Canadian biotechnology company ConjuChem in the early 2000s as an answer to that problem. The molecule takes the GRF(1-29) backbone and introduces four substitutions — commonly described as D-Ala at position 2, Gln at 8, Ala at 15, and Leu at 27 — that blunt enzymatic degradation and improve conformational stability. The version that carries ConjuChem's Drug Affinity Complex (DAC) adds a lysine linker bearing a maleimidopropionyl group, which forms a covalent bond with circulating serum albumin. Because albumin itself has a long residence time in plasma, the conjugated peptide is shielded from renal clearance and proteolysis.

This design split produced the two entities researchers encounter today, and conflating them is the single most common source of confusion in the literature and in commercial listings.

Feature	CJC-1295 with DAC	CJC-1295 no DAC (modified GRF 1-29)
Albumin-binding linker	Present	Absent
Reported circulating duration	Days — a terminal half-life on the order of roughly a week is commonly cited	Minutes — commonly reported near half an hour
Effect on GH exposure	Sustained elevation of the GH/IGF-1 axis	Short, pulse-like stimulation
Typical research framing	Chronic axis stimulation, IGF-1 kinetics	Pulse mimicry, co-administration models with GH secretagogues

Strictly speaking, "CJC-1295 no DAC" is a marketplace name rather than a literature name; the published record generally reserves CJC-1295 for the DAC-conjugated compound and refers to the unconjugated peptide as modified GRF 1-29 or CJC-1295 without DAC. Researchers reading older papers should assume the DAC form unless stated otherwise.

Reported Mechanism of Action

The proposed mechanism is straightforward receptor pharmacology. CJC-1295 binds the growth hormone-releasing hormone receptor (GHRH-R), a class B G-protein-coupled receptor expressed densely on somatotroph cells of the anterior pituitary. Receptor engagement activates adenylate cyclase, raises intracellular cAMP, and promotes both the release of stored growth hormone and the transcription of new GH. Downstream, GH acts on hepatic and peripheral tissue to drive production of insulin-like growth factor 1 (IGF-1), which mediates much of the anabolic signaling attributed to the axis and also provides negative feedback at the hypothalamus and pituitary.

Two features of this mechanism are worth emphasizing because they shape how the compound is studied. First, CJC-1295 acts upstream of the pituitary rather than replacing GH directly, so its output remains subject to somatostatin tone and IGF-1 feedback — a ceiling that exogenous GH bypasses. Second, and counterintuitively, prolonged receptor occupancy does not appear to flatten GH release into a continuous infusion-like pattern. One of the 2006 clinical reports specifically examined this and found that pulsatile GH secretion persisted during continuous stimulation by CJC-1295, with the peptide raising both trough and pulse amplitude rather than abolishing the underlying rhythm. That observation is central to why the compound remains of interest to endocrine researchers: physiological pulsatility appears to be preserved.

What the Published Research Examines

Endocrine pharmacology in healthy adults

The core human dataset comes from early clinical work published in 2006 in The Journal of Clinical Endocrinology and Metabolism, which reported that single administrations in healthy adults produced dose-dependent, several-fold increases in circulating growth hormone alongside elevations in IGF-1 that were sustained for days rather than hours. Those studies are the origin of the widely cited multi-day half-life figures. They were, however, small, short, and conducted in normal volunteers — evidence remains preliminary and should not be read as an efficacy record for any clinical application.

Downstream biomarker changes

A 2009 paper in Growth Hormone & IGF Research extended this by profiling serum proteins in normal adult subjects following activation of the GH/IGF-1 axis by CJC-1295, reporting measurable shifts in the circulating protein profile. This line of work is useful less as a clinical endpoint than as a demonstration that upstream GHRH-receptor stimulation produces detectable, systemic downstream signatures — a point relevant to both biomarker research and doping control.

Preclinical models

In rodent models, once-daily administration of CJC-1295 was reported to normalize growth in the GHRH knockout mouse, a model with an intact pituitary but absent endogenous GHRH signaling. That result supports the receptor-level mechanism described above, though extrapolating growth normalization in a genetically GHRH-deficient animal to any effect in a hormonally intact organism is not supportable on the current evidence.

Analytical chemistry and anti-doping detection

A substantial share of the modern literature is methodological rather than physiological. Papers from 2019 in Drug Testing and Analysis describe an LC-MS/MS confirmation method and an immuno-PCR screening assay for detecting CJC-1295 and related GHRH analogs in equine plasma. An earlier 2010 report in the same journal documented the identification of CJC-1295 in an unknown pharmaceutical preparation — an early signal that the compound had moved outside controlled settings. For laboratories, these papers are valuable as identity-confirmation references and as a reminder that the compound is a monitored substance in sport.

Sociological and behavioral research

A 2016 netnographic study in Substance Use & Misuse analyzed online communities discussing female use of CJC-1295, documenting how information about the peptide circulates, is negotiated, and diverges from the published evidence base. It is a study of discourse, not of pharmacology, but it is one of the more honest windows into the gap between what the literature actually establishes and what is claimed informally.

Areas commonly discussed but thinly evidenced

Topics such as body composition change, sleep architecture, recovery, connective tissue, and cognition appear frequently in secondary discussion of CJC-1295. Controlled human data specific to this compound in those domains is sparse to absent. Where inferences are drawn, they typically come from the broader GH/IGF-1 literature rather than from CJC-1295 trials — a distinction worth preserving in any literature review.

Laboratory Handling: Reconstitution and Storage

CJC-1295 is supplied as a lyophilized (freeze-dried) white powder under vacuum. In that state it is comparatively stable and is generally stored cold and protected from light; long-term storage in a freezer is standard practice for reference material, with refrigeration typical for material in active use. Repeated freeze-thaw cycling is avoided because it is a known driver of peptide aggregation and loss of measurable purity.

Reconstitution is normally performed with bacteriostatic or sterile water introduced slowly against the inner wall of the vial rather than directly onto the peptide cake. Peptides of this class are surface-active and shear-sensitive; vigorous shaking can denature material and produce visible haze or particulate. Gentle swirling until the cake dissolves is the standard approach, followed by visual inspection — a properly reconstituted solution should be clear and free of visible particulate.

Once in solution, stability drops considerably. Reconstituted material is refrigerated, kept out of light, and treated as having a limited working window; the DAC and no-DAC variants are not assumed to behave identically in solution. Laboratories that need extended solution stability generally aliquot to avoid repeated warming of a single vial. Detailed protocols, calculators, and troubleshooting for cloudy or temperature-exposed material are covered in dedicated articles across this hub.

Regulatory and Research-Use Status

CJC-1295 is not an approved drug. It has not been authorized by the FDA for any of the applications discussed on this page, it has no approved indication, and it is not a compounded or prescribable pharmaceutical in the United States. Clinical development by its originator did not carry it to market approval. It is supplied here as a research chemical for laboratory research only — for in vitro work and controlled experimental use by qualified personnel — and it is not intended for human or veterinary use, diagnostic use, or consumption in any form.

Separately, GHRH analogs including CJC-1295 fall within the World Anti-Doping Agency's prohibited classes covering peptide hormones and growth factors, and they are prohibited at all times in sport. The equine detection methods described above exist precisely because the compound is also monitored in animal athletics. Researchers should also be aware that the legal framing of purchase and possession varies by jurisdiction and that intent of use is the operative distinction in most regulatory schemes.

How Researchers Evaluate Supplier Quality

Because CJC-1295 has no pharmacopeial monograph and no approved manufacturing pathway, the burden of quality verification sits entirely with the buyer. Documentation is the only real signal, and it should be batch-specific rather than generic.

Third-party COA per batch. A certificate of analysis from an independent laboratory, tied to the lot number printed on the vial, not a representative document reused across production runs.
HPLC purity. Reverse-phase HPLC chromatograms establish the percentage of the target peptide relative to synthesis-related impurities, deletion sequences, and degradation products. The chromatogram itself is more informative than a single headline percentage.
Mass spectrometry identity. MS confirmation that the observed molecular mass matches the theoretical mass for the specific variant — DAC and no-DAC differ substantially, and MS is where mislabeling between them surfaces.
Batch traceability. A lot number that connects vial, COA, and production run, allowing a laboratory to reconcile anomalous results against a specific batch.
Presentation consistency. Intact vacuum seal, uniform lyophilized cake, correct labeling, and appropriate cold-chain handling in transit.

Peptide identity, purity, and net peptide content are three separate questions. A COA reporting high HPLC purity says nothing about how much of the vial's mass is peptide versus residual salts and water — which is why laboratories doing quantitative work look for peptide content data where it is available.

Where the Open Questions Are

The honest summary is that CJC-1295 has a well-characterized mechanism and a thin outcomes literature. The receptor pharmacology is clear. The pharmacokinetic contrast between the DAC and no-DAC forms is well described. What is not established is what sustained, long-term upstream stimulation of the GH/IGF-1 axis actually produces over months or years in intact organisms — including whether receptor desensitization emerges, how IGF-1 feedback reshapes the response over time, and what the long-term metabolic consequences of chronically elevated IGF-1 might be.

Other gaps are conspicuous. Human data in older adults, in individuals with metabolic dysfunction, and in females specifically remain limited. Comparative work against other GHRH analogs such as sermorelin and tesamorelin, or against GH secretagogue receptor agonists, is largely absent for this compound. And the frequently discussed effects on sleep, recovery, and body composition have not been isolated in controlled CJC-1295 trials. For researchers designing work in this space, those gaps are the interesting part — and they are the reason careful, well-documented laboratory work still has something to add.

Research-grade CJC-1295: Real Peptides supplies CJC-1295 for laboratory research with a published third-party Certificate of Analysis for every batch. Research use only.

Explore CJC-1295 research on Real Peptides

The articles below go deeper on the questions researchers ask most about CJC-1295.

Research questions

Reconstitution, storage & handling

Research timelines & mechanisms

Legal & regulatory

Safety & side effects

Stacks & comparisons

Buying & quality

CJC-1295 Myths Cost Money Health — Real Peptides

References

Peer-reviewed sources on CJC-1295 indexed in PubMed, listed for research context. Real Peptides supplies CJC-1295 for laboratory research use only.

Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Substance use & misuse, 2016. PMID 26771670. doi:10.3109/10826084.2015.1082595
Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug testing and analysis, 2010. PMID 21204297. doi:10.1002/dta.233
Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2009. PMID 19386527. doi:10.1016/j.ghir.2009.03.001
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of clinical endocrinology and metabolism, 2006. PMID 16352683. doi:10.1210/jc.2005-1536
Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American journal of physiology. Endocrinology and metabolism, 2006. PMID 16822960. doi:10.1152/ajpendo.00201.2006
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of clinical endocrinology and metabolism, 2006. PMID 17018654. doi:10.1210/jc.2006-1702
Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 2005. PMID 15817669. doi:10.1210/en.2004-1286

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Both share the same modified GRF(1-29) backbone with four stabilizing substitutions. The DAC version adds a maleimidopropionyl linker that binds covalently to serum albumin, extending circulating duration to a reported timescale of days. The no-DAC form, often called modified GRF 1-29, lacks that linker and is reported to clear within roughly half an hour, producing a short pulse rather than sustained axis stimulation.

No, though all three are GHRH analogs acting at the same receptor. Sermorelin is the unmodified GRF(1-29) fragment. Tesamorelin is a trans-3-hexenoyl-modified GRF(1-44) analog and is the only member of the group with FDA approval, for a specific indication. CJC-1295 differs from both through its four amino acid substitutions and, in the DAC form, its albumin-binding linker.

No. CJC-1295 has no FDA approval for any indication, no approved manufacturing standard, and no pharmacopeial monograph. Clinical development by its originator did not reach market authorization. Material sold by research suppliers is designated for laboratory research only and is not intended for human or veterinary use, diagnostic application, or consumption.

GHRH analogs fall within World Anti-Doping Agency prohibited classes covering peptide hormones and growth factors, and are banned at all times in sport. That status drove development of detection assays, including LC-MS/MS confirmation methods and immuno-PCR screens for CJC-1295 in equine plasma published in 2019. An earlier 2010 report also documented identification of the compound in an unknown pharmaceutical preparation.

A useful COA is batch-specific and issued by an independent laboratory. It should show reverse-phase HPLC data establishing purity against synthesis impurities and degradation products, mass spectrometry confirming the observed molecular mass matches the theoretical mass for the specific variant, and a lot number that traces back to the vial. Net peptide content, where reported, adds further quantitative value.

Early clinical work published in 2006 examined this directly and reported that pulsatile growth hormone secretion persisted during continuous stimulation by CJC-1295, with the peptide appearing to raise both baseline and pulse amplitude rather than flattening the underlying rhythm. The finding is frequently cited in mechanism discussions, though it comes from small studies in healthy adults and evidence remains preliminary.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA